We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

102 hedge funds and large institutions have $102M invested in Zentalis Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

604% more call options, than puts

Call options by funds: $971K | Put options by funds: $138K

170% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 10

85% more capital invested

Capital invested by funds: $54.9M → $102M (+$46.8M)

19% more funds holding

Funds holding: 86 → 102 (+16)

5.23% more ownership

Funds ownership: 56.18% → 61.41% (+5.2%)

7% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 28

Holders
102
Holders Change
+16
Holders Change %
+18.6%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
27
Increased
30
Reduced
28
Closed
10
Calls
$971K
Puts
$138K
Net Calls
+$833K
Net Calls Change
+$806K

Top Buyers

Rank Fund Capital Flow
1
SCM
Squadron Capital Management
Illinois
+$9.38M
2
Two Sigma Investments
Two Sigma Investments
New York
+$3.84M
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$1.6M
4
Millennium Management
Millennium Management
New York
+$1.59M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.45M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$2.44M
2
GCP
GSA Capital Partners
United Kingdom
-$1.42M
3
UBS Group
UBS Group
Switzerland
-$1.34M
4
Morgan Stanley
Morgan Stanley
New York
-$1.17M
5
WP
Woodline Partners
California
-$683K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$1.08M +$890K +344,466 +291%
Marshall Wace
27
Marshall Wace
United Kingdom
$919K +$374K +144,855 +58%
VPM
28
Vanguard Portfolio Management
Pennsylvania
$844K +$931K +360,600 New
PLC
29
Peapod Lane Capital
New York
$835K -$212K -81,993 -18%
Morgan Stanley
30
Morgan Stanley
New York
$819K -$1.17M -453,447 -56%
XT
31
XTX Topco
Cayman Islands
$755K -$656K -254,200 -44%
VFT
32
Vanguard Fiduciary Trust
Pennsylvania
$712K +$786K +304,471 New
Creative Planning
33
Creative Planning
Kansas
$667K +$64.6K +25,000 +10%
Fidelity Investments
34
Fidelity Investments
Massachusetts
$664K +$105K +40,609 +17%
CF
35
CDC Financial
Illinois
$664K +$733K +283,762 New
ACM
36
Anfield Capital Management
California
$642K +$82.4K +31,911 +13%
Dimensional Fund Advisors
37
Dimensional Fund Advisors
Texas
$634K +$454K +175,771 +183%
SCM
38
Stonepine Capital Management
Oregon
$630K -$503K -194,600 -42%
WP
39
Woodline Partners
California
$623K -$683K -264,550 -50%
State Street
40
State Street
Massachusetts
$584K -$57.1K -22,100 -8%
SEI Investments
41
SEI Investments
Pennsylvania
$448K +$63.1K +24,451 +15%
UBS Group
42
UBS Group
Switzerland
$364K -$1.34M -518,894 -77%
QL
43
Quarry LP
New York
$351K +$46.5K +18,000 +14%
ACM
44
ADAR1 Capital Management
Texas
$338K +$167K +64,636 +81%
PAM
45
Panagora Asset Management
Massachusetts
$327K +$137K +53,050 +61%
Invesco
46
Invesco
Georgia
$294K -$162K -62,815 -33%
Northern Trust
47
Northern Trust
Illinois
$277K +$65.4K +25,315 +27%
Hudson Bay Capital Management
48
Hudson Bay Capital Management
Connecticut
$274K +$302K +117,127 New
ESBC
49
E.S. Barr & Co
Kentucky
$257K +$136K +52,500 +91%
SFCM
50
Seven Fleet Capital Management
California
$257K +$284K +110,000 New
1
2
3 4 5

ZNTL Hedge Fund Activity: Q1 2026 in Review

102 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2026, worth a combined $102M — up 85% from $54.9M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ZNTL positions and 10 closed out — a net gain of 17 holders — while 30 added to existing stakes and 28 trimmed.

The largest buyer was Squadron Capital Management, opening a new position worth an estimated $9.38M. The largest seller was Renaissance Technologies, cutting an estimated $2.44M.

  • 102 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2026, up from 86 in Q4 2025.
  • Funds reported $102M of Zentalis Pharmaceuticals stock for Q1 2026, up 85% quarter-over-quarter.
  • 27 funds opened new Zentalis Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +17 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q1 2026 was Squadron Capital Management, an estimated $9.38M added.
  • The largest Zentalis Pharmaceuticals seller in Q1 2026 was Renaissance Technologies, an estimated $2.44M sold.

Based on aggregated 13F filings for Q1 2026.